Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct;20(10):6948-6959.
doi: 10.1002/alz.14169. Epub 2024 Aug 4.

Association of caffeine consumption with cerebrospinal fluid biomarkers in mild cognitive impairment and Alzheimer's disease: A BALTAZAR cohort study

David Blum  1   2 , Emeline Cailliau  3 , Hélène Béhal  3 , Jean-Sébastien Vidal  4 , Constance Delaby  5   6 , Luc Buée  1   2 , Bernadette Allinquant  7 , Audrey Gabelle  8 , Stéphanie Bombois  2   9 , Sylvain Lehmann  5 , Susanna Schraen-Maschke  1   2 , Olivier Hanon  4 ; BALTAZAR study group
Collaborators, Affiliations

Association of caffeine consumption with cerebrospinal fluid biomarkers in mild cognitive impairment and Alzheimer's disease: A BALTAZAR cohort study

David Blum et al. Alzheimers Dement. 2024 Oct.

Abstract

Introduction: We investigated the link between habitual caffeine intake with memory impairments and cerebrospinal fluid (CSF) biomarkers in mild cognitive impairment (MCI) and Alzheimer's disease (AD) patients.

Methods: MCI (N = 147) and AD (N = 116) patients of the Biomarker of AmyLoid pepTide and AlZheimer's diseAse Risk (BALTAZAR) cohort reported their caffeine intake at inclusion using a dedicated survey. Associations of caffeine consumption with memory impairments and CSF biomarkers (tau, p-tau181, amyloid beta 1-42 [Aβ1-42], Aβ1-40) were analyzed using logistic and analysis of covariance models.

Results: Adjusted on Apolipoprotein E (APOE ε4), age, sex, education level, and tobacco, lower caffeine consumption was associated with higher risk to be amnestic (OR: 2.49 [95% CI: 1.13 to 5.46]; p = 0.023) and lower CSF Aβ1-42 (p = 0.047), Aβ1-42/Aβ1-40 (p = 0.040), and Aβ1-42/p-tau181 (p = 0.020) in the whole cohort.

Discussion: Data support the beneficial effect of caffeine consumption to memory impairments and CSF amyloid markers in MCI and AD patients.

Highlights: We studied the impact of caffeine consumption in the BALTAZAR cohort. Low caffeine intake is associated with higher risk of being amnestic in MCI/AD patients. Caffeine intake is associated with CSF biomarkers in AD patients.

Keywords: Alzheimer's disease; CSF biomarkers; caffeine; memory; mild cognitive impairment.

PubMed Disclaimer

Conflict of interest statement

David Blum DB is a (non‐appointed) member of the scientific advisory board of Marvel Biosciences Corp. developing an A2AR antagonist but has no conflict of interest regarding the present work. Olivier Hanon received personal payment from Bayer, Servier, AstraZeneca, Boston Scientific, Vifor, BMS, Boehringer‐Ingelheim, and Pfizer for lectures and/or consulting services. Jean Sebastien Vidal received payment from Bayer for lectures made to a non‐profit medical association. Sylvain Lehmann received for his institution support from the following: H2020 MARIE SKŁODOWSKA‐CURIE “MIRIADE Multi‐omics Interdisciplinary Research Integration to Address DEmentia diagnosis,” ANR Flash Covid: “ProteoCOVID: Clinical proteomic characterization of the SARS‐CoV‐2 Spike protein to optimize its detection and the development of serological assays,” ANR “Silk_road: The Stable Isotope Labeling Kinetics (SILK) road to investigate human protein turnover in blood and cerebrospinal fluid,” EUROMET EMPIR “NeuroMet2 project: Metrology and Innovation for early diagnosis and accurate stratification of patients with neurodegenerative diseases.” During the past 36 months, he had a patent issued for “Procédé de préparation d'un échantillon peptidique” Brevet INPI n°1905247 du 20/05/2019 du CHU DE MONTPELLIER, UNIVERSITÉ DE MONTPELLIER and SPOT TO LAB. He received personal payment for participating on the Roche Diagnostic board on CSF biomarkers. Stéphanie Bombois, Bernadette Allinquant, Christiane Baret‐Rose, Jean‐Marc Tréluyer, Hendy Abdoul, Patrick Gelé, Christine Delmaire, Jean‐François Mangin, and Evelyne Galbrun have no conflicts of interest. Fredéric Blanc received honoraria from Roche and Biogen for presentations. He received payment to his institution as the national coordinator for the clinical trial DELPHIA for patients with dementia with Lewy bodies (Eisai). He received payment to his institution as the national coordinator for the clinical trial GRADUATE for patients with AD. Luc Buée received support for the present manuscript from LabEx DISTALZ. He received grants or contracts from the French National Research Agency (ANR) Fondation pour la Recherche Médicale (FRM). In the past 36 months, he had a patent on anti‐tau therapy issued. Jacques Touchon received payment or honoraria as chairman of CTAD. He received contracts from Regenlife and consulting fees from Regenlife. He is chairman of JT Conseil society. Jacques Hugon received grants or contracts from Protekt Therapeutics and consulting fees from Protekt Therapeutics. He is principal investigator of RECAGE project European Union H20/20 program and he is member of the scientific board of Fondation Philippe Chatrier, Paris, France. Bruno Vellas received grants or contracts from Biogen, Roche, and Lilly; consulting fees from Roche, Lily, Biogen, and Cerellis; and is part of WHO's ICOPE program (unpaid position). AthanBase Benetos is the president of the European Geriatric Medicine Society (unpaid position). He received support for attending meetings and/or travel from Fukuda company, for the Congress of the European Society of Hypertension, and received royalties or licenses from Cambridge University Editions. Gilles Berrut received a grant from Boehringer Ingelheim and consulting fees from Boehringer Ingelheim, Smart macadam Institut, bien vieillir Korian. Elena Paillaud has no conflicts of interest. David Wallon, Giovanni Castelnovo, Lisette Volpe‐Gillot, Marc Paccalin, Philippe Robert, and Vincent Camus have no conflicts of interest. Olivier Godefroy received support to his institution for attending meetings and/or travel from BRISTOL‐MYERS SQUIBB, ROCHE SAS, BIOGEN FRANCE SAS. Joël Belmin received consulting fees from Pfizer and honoraria from Novartis Pharmaceuticals. Pierre Vandel is president of the “Société Francophone de Psychogériatrie et Psychiatrie de la Personne Agée” (SF3PA) and received consulting fees from Eisai. Jean‐Luc Novella, Emmanuelle Duron, Anne‐Sophie Rigaud, Susanna Schraen‐Maschke, Bernard Sablonnière, and Audrey Gabelle have no conflicts of interest. Author disclosures are available in the supporting information.

References

    1. De Strooper B, Karran E. The cellular phase of Alzheimer's disease. Cell. 2016;164:603‐615. doi:10.1016/j.cell.2015.12.056 - DOI - PubMed
    1. Lambert J‐C, Ramirez A, Grenier‐Boley B, Bellenguez C. Step by step: towards a better understanding of the genetic architecture of Alzheimer's disease. Mol Psychiatry. 2023;28:2716‐2727. doi:10.1038/s41380-023-02076-1 - DOI - PMC - PubMed
    1. Reitz C, Brayne C, Mayeux R. Epidemiology of Alzheimer disease. Nat Rev Neurol. 2011;7:137‐152. doi:10.1038/nrneurol.2011.2 - DOI - PMC - PubMed
    1. Fredholm BB, Bättig K, Holmén J, Nehlig A, Zvartau EE. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev. 1999;51:83‐133. - PubMed
    1. Freedman ND, Park Y, Abnet CC, Hollenbeck AR, Sinha R. Association of coffee drinking with total and cause‐specific mortality. N Engl J Med. 2012;366:1891‐1904. doi:10.1056/NEJMoa1112010 - DOI - PMC - PubMed